Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated today, March 1, 2021:
Effective April 1, 2021:
- Biologic Immunomodulators
- Multiple Sclerosis
- Multiple Sclerosis IV
- Afrezza
- GLP1
- Insulin
- Insulin Combination
- Methotrexate Injectable
- CFTR
- Hereditary Angioedema
- Interstitial Lung Disease (ILD)
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this publication, please contact your BCBSKS provider representative/consultant.